The stock of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) is now priced at $34.22 and the shares are 21.62 points up or 171.59% higher compared to its previous closing price of $12.6. The stock had 44.642 million contracts set over the past session. AIMT shares’ daily volume is compared to its average trading volume at 1.107 million shares. However, it has a float of 50.99 million and although its performance was 174.2% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the AIMT share price recently placing at $34.15 to $34.28. However, some brokerage firms have priced the stock below the average, including one that has called $15.

The shorts are running away from the Aimmune Therapeutics, Inc. stock, with the latest data on short interest released on August 14, 2020, showing that short interest numbers in the AIMT shares have declined. Short interest in the stock represents just 36.12% of its float, but the volume has dropped by -354874. The volume of shorted shares dropped to 18.416 million from 18.771 million shares over the last two weeks. The average intraday trading volume has been 875010 shares, which means that days to cover moved to roughly 21.047138.

In the last trading session, Aimmune Therapeutics, Inc. (NASDAQ:AIMT) raised by $21.74 over the week and gained $20.61 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $37. The stock recorded its established 52-week high on 01/16/20.

Since 03/17/20, the stock has traded to a low of $10.09 at 239.15%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 0.77. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.

Looking at current readings, Aimmune Therapeutics, Inc.’s two-week RSI is 89.34. This suggests that the stock is oversold at the moment and that AIMT shares’ price movement remains not stable. The stochastic readings are equally revealing at 42.99% meaning the AIMT share price is currently in neutral territory.

The technical chart shows that the AIMT stock will likely settle at between $34.28 and $34.35 per share. However, if the stock dips below $34.15, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $34.09.

Currently, the stock is trading in the green of MACD, with a reading of 4.58. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.

Analysts at Maxim Group assigned AIMT a rating of Outperform in their intiating review released on July 13. H.C. Wainwright analysts see the stock as a Neutral, but they also dropped the share’s target price from $30 to $15 in a flash note released to investors on May 12. JMP Securities seeing the stock struggling downgraded it from Mkt Outperform to Mkt Perform on March 18.

The average rating for the AIMT equity is 2.25 and is currently gathering a bullish momentum. Of 12 analysts tracking Aimmune Therapeutics, Inc. polled by Reuters, 8 rated AIMT as a hold. The remaining 4 analysts were split evenly. However, the split wasn’t equal as a majority (4) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.